The impact of host pharmacogenetics on antiretroviral drug disposition

Current Infectious Disease Reports

Volumn 8, Issue 5, 2006, Pages 401-408

  Owen, Andrew ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C2; ABC TRANSPORTER C4; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; MULTIDRUG RESISTANCE PROTEIN 1; NELFINAVIR; NEVIRAPINE; PREGNANE X RECEPTOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE; ZIDOVUDINE 5' TRIPHOSPHATE;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; GENE LOCUS; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIGENE FAMILY; NONHUMAN; PHARMACOGENETICS; PHENOTYPIC VARIATION; PREDICTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS CELL INTERACTION;

EID: 33749038880     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-006-0052-2     Document Type: Review

References (64)

1. d'arminio Monforte A, Cozzi-Lepri A, Phillips A, et al.: Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of Antiretroviral-Naive Patients. J Acquir Immune Defic Syndr 2005, 38:407-416.
2. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al.: Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003, 138:620-626.
3. Boffito M, Acosta E, Burger D, et al.: Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antivir Ther 2005, 10:375-392.
4. Kivisto KT, Niemi M, Fromm MF: Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol 2004, 18:621-626.
5. Lamba J, Strom S, Venkataramanan R, et al.: MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther 2006, 79:325-338.
6. Lau YY, Okochi H, Huang Y, Benet LZ: Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 2006, 316:762-771.
7. Lau YY, Wu CY, Okochi H, Benet LZ: Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J Pharmacol Exp Ther 2004, 308:1040-1045.
8. Tirona RG, Leake BF, Wolkoff AW, Kim RB: Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 2003, 304:223-228.
9. Ho RH, Kim RB: Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005, 78:260-277.
10. Haas DW, Bartlett J, Andersen J, et al.: Pharmacogenetics of nevirapine and hepatotoxicity: NWCS220, an ACTG collaborative study. http://www.retroconference.org/2005/cd/Abstracts/24568.htm. Accessed July 17, 2006.
11. Owen A, Almond L, Hartkoorn R, et al.: Relevance of drug transporttes and drug metabolism enzymes to nevirapine: superimposition of host genotype. http://www.retroconference.org/2005/cd/Abstracts/24878.htm. Accessed July 17, 2006.
12. Marzolini C, Leake B, Schwarz U, et al.: Evaluation of efavirenz transport by P-glycoprotein and uptake transporters. http://www.retroconference.org/2006/Abstracts/26189.htm. Accessed July 17, 2006.
13. Fletcher CV, Kawle SP, Kakuda TN, et al.: Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS 2000, 14:2137-2144.
14. Antonelli G, Turriziani O, Cianfriglia M, et al.: Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein. AIDS Res Hum Retroviruses 1992, 8:1839-1844.
15. Schuetz JD, Connelly MC, Sun D, et al.: MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999, 5:1048-1051.
16. Wijnholds J, Mol CA, van Deemter L, et al.: Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 2000, 97:7476-7481.
17. Ritzel MW, Yao SY, Ng AM, et al.: Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/ nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol Membr Biol 1998, 15:203-211.
18. Yao SY, Ng AM, Sundaram M, et al.: Transport of antiviral 3′-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol Membr Biol 2001, 18:161-167.
19. Frohlich M, Hoffmann MM, Burhenne J, et al.: Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. Br J Clin Pharmacol 2004, 58:443-444.
20. Mouly SJ, Matheny C, Paine MF, et al.: Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther 2005, 78:605-618.
21. Wojnowski L, Hustert E, Klein K, et al.: Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 [letter]. J Natl Cancer Inst 2002, 94:630-631; author reply 631-632.
22. Lee SJ, Bell DA, Coulter SJ, et al.: Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. J Pharmacol Exp Ther 2005, 313:302-309.
23. Haas DW, Smeaton LM, Shafer RW, et al.: Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult AIDS Clinical Trials Group study. J Infect Dis 2005, 192:1931-1942.
24. Klein K, Lang T, Saussele T, et al.: Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005, 15:861-873.
25. Lang T, Klein K, Fischer J, et al.: Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001, 11:399-415.
26. Owen A, Cook C, Liptrott N, et al.: The impact of Cytochrome P450 polymorphisms on expression of drug-metabolising enzymes in lymphocytes. Drug Metabolism Reviews 2006, 38:5-5.
27. Haas DW, Ribaudo HJ, Kim RB, et al.: Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004, 18:2391-2400.
28. Rodriguez-Novoa S, Barreiro P, Rendon A, et al.: Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005, 40:1358-1361.
29. Rotger M, Colombo S, Furrer H, et al.: Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005, 15:1-5.
30. Motsinger A, Ritchie M, Shafer R, et al.: Multilocus gene-gene interactions may predict efavirenz pharmacokinetics and treatment response: analysis NWCS 213 of ACTG study 384. http://www.retroconference.org/2006/Abstracts/27301.htm. Accessed July 17, 2006.
31. Saitoh A, Fletcher C, Brundage R, et al.: CYP2B6-G516T polymorphisms influence plasma concentrations of efavirenz in HIV-1-infected children receiving HAART. http://www.retroconference.org/2006/Abstracts/ 27070.htm. Accessed July 17, 2006.
32. Rotger M, Colombo S, Cavassini M, et al.: Genetic variability of CYP2B6 in individuals with extremely high efavirenz plasma concentrations. http://www.retroconference.org/2006/Abstracts/27331.htm. Accessed July 17, 2006.
33. Wang H, Faucette S, Sueyoshi T, et al.: A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem 2003, 278:14146-14152.
34. Sueyoshi T, Kawamoto T, Zelko I, et al.: The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 1999, 274:6043-6046.
35. Maring JG, Groen HJ, Wachters FM, et al.: Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J 2005, 5:226-243.
36. Wang D, Johnson AD, Papp AC, et al.: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 2005, 15:693-704.
37. Marzolini C, Paus E, Buclin T, Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004, 75:13-33.
38. Owen A, Chandler B, Back DJ: The implications of P-glycoprotein in HIV: friend or foe? Fundam Clin Pharmacol 2005, 19:283-296.
39. Saitoh A, Singh KK, Powell CA, et al.: An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 2005, 19:371-380.
40. Verstuyft C, Marcellin F, Morand-Joubert L, et al.: Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. AIDS 2005, 19:2127-2131.
41. Marquie-Beck J, Ellis R, Buzzell M, et al.: Multi-drug resistance-1 gene and indinavir concentration in cerebrospinal fluid and plasma from HIV-infected individuals. http://www.retroconference.org/2006/Abstracts/ 27807.htm. Accessed July 17, 2006.
42. Leschziner G, Zabaneh D, Pirmohamed M, et al.: Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. Pharmacogenet Genomics 2006, 16:439-450.
43. Wang H, Hao B, Zhou K, et al.: Linkage disequilibrium and haplotype architecture for two ABC transporter genes (ABCC1 and ABCG2) in Chinese population: implications for pharmacogenomic association studies. Ann Hum Genet 2004, 68:563-573.
44. Colombo S, Soranzo N, Rotger M, et al.: Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet Genomics 2005, 15:599-608.
45. Owen A, Chandler B, Bray PG, et al.: Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J Virol 2004, 78:12022-12029.
46. Hitzl M, Drescher S, van der Kuip H, et al.: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001, 11:293-298.
47. Woodahl EL, Yang Z, Bui T, et al.: MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS 2005, 19:1617-1625.
48. Gwee PC, Tang K, Sew PH, et al.: Strong linkage disequilibrium at the nucleotide analogue transporter ABCC5 gene locus. Pharmacogenet Genomics 2005, 15:91-104.
49. Owen RP, Gray JH, Taylor TR, et al.: Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2. Pharmacogenet Genomics 2005, 15:83-90.
50. Owen RP, Lagpacan LL, Taylor TR, et al.: Functional characterization and haplotype analysis of polymorphisms in the human equilibrative nucleoside transporter, ENT2. Drug Metab Dispos 2006, 34:12-15.
51. Saito S, Iida A, Sekine A, et al.: Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR. J Hum Genet 2002, 47:147-171.
52. Anderson PL, Lamba J, Aquilante CL, et al.: Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr 2006, 42:441-449.
53. Li JH, Xu JQ, Cao XM, et al.: Influence of the ORM1 phenotypes on serum unbound concentration and protein binding of quinidine. Clin Chim Acta 2002, 317:85-92.
54. Fournier T, Medjoubi NN, Porquet D: Alpha-1-acid glycoprotein. Biochim Biophys Acta 2000, 1482:157-171.
55. McCollam PL, Crouch MA, Arnaud P: Caucasian versus African-American differences in orosomucoid: potential implications for therapy. Pharmacotherapy 1998, 18:620-626.
56. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001, 276:14581-14587.
57. Lehmann JM, McKee DD, Watson MA, et al.: The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998, 102:1016-1023.
58. Dussault I, Lin M, Hollister K, et al.: Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem 2001, 276:33309-33312.
59. Hariparsad N, Nallani SC, Sane RS, et al.: Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 2004, 44:1273-1281.
60. Owen A, Chandler B, Back DJ, Khoo SH: Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. Antivir Ther 2004, 9:819-821.
61. Lamba J, Lamba V, Schuetz E: Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 2005, 6:369-383.
62. Dorr P, Westby M, Dobbs S, et al.: Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005, 49:4721-4732.
63. Mould DR, Zhang X, Nieforth K, et al.: Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther 2005, 77:515-528.
64. Walker DK, Abel S, Comby P, et al.: Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 2005, 33:587-595.